GSK abandons Ionis' FDA-ready inotersen as new CEO sweeps out rare disease efforts
Just three months after Ionis spelled out positive Phase III efficacy data on its top prospect inotersen, GlaxoSmithKline is sweeping their alliance on the drug out the back door, along with rights to another treatment they have rights to.
It’s a stunning 11th hour reversal for Ionis $IONS, which says it now plans to push for an FDA approval of inotersen on its own this fall as it thinks through whether it will commercialize or co-commercialize in the US on its own.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
